Literature DB >> 27031928

In vivo xenogeneic scaffold fate is determined by residual antigenicity and extracellular matrix preservation.

Maelene L Wong1, Janelle L Wong2, Natalia Vapniarsky3, Leigh G Griffiths4.   

Abstract

The immunological potential of animal-derived tissues and organs is the critical hurdle to increasing their clinical implementation. Glutaraldehyde-fixation cross-links proteins in xenogeneic tissues (e.g., bovine pericardium) to delay immune rejection, but also compromises the regenerative potential of the resultant biomaterial. Unfixed xenogeneic biomaterials in which xenoantigenicity has been ameliorated and native extracellular matrix (ECM) architecture has been maintained have the potential to overcome limitations of current clinically utilized glutaraldehyde-fixed biomaterials. The objective of this work was to determine how residual antigenicity and ECM architecture preservation modulate recipient immune and regenerative responses towards unfixed bovine pericardium (BP) ECM scaffolds. Disruption of ECM architecture during scaffold generation, with either SDS-decellularization or glutaraldehyde-fixation, stimulated recipient foreign body response and resultant fibrotic encapsulation following leporine subpannicular implantation. Conversely, BP scaffolds subjected to stepwise removal of hydrophilic and lipophilic antigens using amidosulfobetaine-14 (ASB-14) maintained native ECM architecture and thereby avoided fibrotic encapsulation. Removal of hydrophilic and lipophilic antigens significantly decreased local and systemic graft-specific, adaptive immune responses and subsequent calcification of BP scaffolds compared to scaffolds undergoing hydrophile removal only. Critically, removal of antigenic components and preservation of ECM architecture with ASB-14 promoted full-thickness recipient non-immune cellular repopulation of the BP scaffold. Further, unlike clinically utilized fixed BP, ASB-14-treated scaffolds fostered rapid intimal and medial vessel wall regeneration in a porcine carotid patch angioplasty model. This work highlights the importance of residual antigenicity and ECM architecture preservation in modulating recipient immune and regenerative responses towards xenogeneic biomaterial generation.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Antigen removal; Decellularization; Extracellular matrix; Immune response; Vascular regenerative medicine; Xenogeneic scaffold

Mesh:

Substances:

Year:  2016        PMID: 27031928      PMCID: PMC5289067          DOI: 10.1016/j.biomaterials.2016.03.024

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  41 in total

1.  In vitro toxicity of various classes of test agents using the neutral red assay on a human three-dimensional physiologic skin model.

Authors:  D Triglia; S S Braa; C Yonan; G K Naughton
Journal:  In Vitro Cell Dev Biol       Date:  1991-03

2.  A porcine-derived acellular dermal scaffold that supports soft tissue regeneration: removal of terminal galactose-alpha-(1,3)-galactose and retention of matrix structure.

Authors:  Hui Xu; Hua Wan; Wenqi Zuo; Wendell Sun; Rick T Owens; John R Harper; David L Ayares; David J McQuillan
Journal:  Tissue Eng Part A       Date:  2009-07       Impact factor: 3.845

3.  The role of protein solubilization in antigen removal from xenogeneic tissue for heart valve tissue engineering.

Authors:  Maelene L Wong; J Kent Leach; Kyriacos A Athanasiou; Leigh G Griffiths
Journal:  Biomaterials       Date:  2011-07-31       Impact factor: 12.479

Review 4.  Tissue-engineered heart valve scaffolds.

Authors:  Pascal M Dohmen; Wolfgang Konertz
Journal:  Ann Thorac Cardiovasc Surg       Date:  2009-12       Impact factor: 1.520

Review 5.  Mesh biocompatibility: effects of cellular inflammation and tissue remodelling.

Authors:  Karsten Junge; Marcel Binnebösel; Klaus T von Trotha; Raphael Rosch; Uwe Klinge; Ulf P Neumann; Petra Lynen Jansen
Journal:  Langenbecks Arch Surg       Date:  2011-04-01       Impact factor: 3.445

6.  Decellularization of bovine pericardium for tissue-engineering by targeted removal of xenoantigens.

Authors:  Ana C Gonçalves; Leigh G Griffiths; Russell V Anthony; E Christopher Orton
Journal:  J Heart Valve Dis       Date:  2005-03

7.  Transplantation material bovine pericardium: biomechanical and immunogenic characteristics after decellularization vs. glutaraldehyde-fixing.

Authors:  Jörn Hülsmann; Katja Grün; Sonya El Amouri; Mareike Barth; Katrin Hornung; Carlheinz Holzfuß; Artur Lichtenberg; Payam Akhyari
Journal:  Xenotransplantation       Date:  2012 Sep-Oct       Impact factor: 3.907

8.  The decellularized porcine heart valve matrix in tissue engineering: platelet adhesion and activation.

Authors:  Marie-Theres Kasimir; Guenter Weigel; Jyotindra Sharma; Erwin Rieder; Gernot Seebacher; Ernst Wolner; Paul Simon
Journal:  Thromb Haemost       Date:  2005-09       Impact factor: 5.249

9.  Interaction of mixture of anionic surfactants with collagen.

Authors:  J Krejcí
Journal:  Int J Cosmet Sci       Date:  2007-04       Impact factor: 2.970

10.  Changes of the Structural and Biomechanical Properties of the Bovine Pericardium after the Removal of α-Gal Epitopes by Decellularization and α-Galactosidase Treatment.

Authors:  Jinhae Nam; Sun-Young Choi; Si-Chan Sung; Hong-Gook Lim; Seong-Sik Park; Soo-Hwan Kim; Yong Jin Kim
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2012-12-07
View more
  25 in total

Review 1.  Extracellular Matrix-Based Strategies for Immunomodulatory Biomaterials Engineering.

Authors:  Andrew T Rowley; Raji R Nagalla; Szu-Wen Wang; Wendy F Liu
Journal:  Adv Healthc Mater       Date:  2019-02-04       Impact factor: 9.933

Review 2.  The extracellular matrix of the gastrointestinal tract: a regenerative medicine platform.

Authors:  George S Hussey; Timothy J Keane; Stephen F Badylak
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-07-12       Impact factor: 46.802

3.  Xenogeneic Decellularized Scaffold: A Novel Platform for Ovary Regeneration.

Authors:  Wen-Yue Liu; Shi-Gang Lin; Ru-Yi Zhuo; Yuan-Yuan Xie; Wei Pan; Xian-Feng Lin; Fei-Xia Shen
Journal:  Tissue Eng Part C Methods       Date:  2017-01-10       Impact factor: 3.056

4.  Graft-specific immune tolerance is determined by residual antigenicity of xenogeneic extracellular matrix scaffolds.

Authors:  Ailsa J Dalgliesh; Mojtaba Parvizi; Manuela Lopera-Higuita; Jeny Shklover; Leigh G Griffiths
Journal:  Acta Biomater       Date:  2018-08-18       Impact factor: 8.947

Review 5.  The useful agent to have an ideal biological scaffold.

Authors:  Raziyeh Kheirjou; Jafar Soleimani Rad; Ahad Ferdowsi Khosroshahi; Leila Roshangar
Journal:  Cell Tissue Bank       Date:  2020-11-22       Impact factor: 1.522

Review 6.  Small Diameter Xenogeneic Extracellular Matrix Scaffolds for Vascular Applications.

Authors:  Manuela Lopera Higuita; Leigh G Griffiths
Journal:  Tissue Eng Part B Rev       Date:  2019-11-27       Impact factor: 6.389

7.  Effect of Urea and Thiourea on Generation of Xenogeneic Extracellular Matrix Scaffolds for Tissue Engineering.

Authors:  Maelene L Wong; Janelle L Wong; Rebecca M Horn; Kimberley C Sannajust; Dawn A Rice; Leigh G Griffiths
Journal:  Tissue Eng Part C Methods       Date:  2016-06-27       Impact factor: 3.056

8.  Chronic graft-specific cell-mediated immune response toward candidate xenogeneic biomaterial.

Authors:  Katherine V Gates; Leigh G Griffiths
Journal:  Immunol Res       Date:  2018-04       Impact factor: 2.829

9.  Immunoproteomic Identification of Noncarbohydrate Antigens Eliciting Graft-Specific Adaptive Immune Responses in Patients with Bovine Pericardial Bioprosthetic Heart Valves.

Authors:  Katherine V Gates; Qi Xing; Leigh G Griffiths
Journal:  Proteomics Clin Appl       Date:  2018-12-19       Impact factor: 3.494

10.  Antigen removal process preserves function of small diameter venous valved conduits, whereas SDS-decellularization results in significant valvular insufficiency.

Authors:  Manuela Lopera Higuita; Leigh G Griffiths
Journal:  Acta Biomater       Date:  2020-03-07       Impact factor: 8.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.